Pfizer (NYSE:PFE) Stock Price Down 1.7% - Here's What Happened

Key Points

• Pfizer shares were down 1.7% midday to about $25.65 on lower volume; the company has a $145.8B market cap, a P/E of 14.9 and recently announced a $0.43 quarterly dividend (a 6.7% yield with a 100% payout ratio).
• Pipeline momentum includes a COPD candidate moving into Phase 2/3, a large Phase 3 lung‑cancer trial
• Analyst and investor sentiment is mixed: MarketBeat shows a consensus rating of "Hold" with an average target of $27.88, while commentators flag valuation and post‑COVID revenue/pricing risks that could limit near‑term upside.

Pfizer Inc. (NYSE:PFE - Get Free Report) was down 1.7% during mid-day trading on Friday . The stock traded as low as $25.51 and last traded at $25.6460. Approximately 45,354,101 shares changed hands during trading, a decline of 7% from the average daily volume of 48,821,633 shares. The stock had previously closed at $26.10.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pipeline expansion — Pfizer advanced a COPD candidate into a Phase 2/3 trial, adding a late‑stage asset to its post‑COVID respiratory pipeline that could meaningfully expand future revenue if successful. Pfizer Advances New COPD Candidate Into Phase 2/3
• Positive Sentiment: Major oncology push — Pfizer launched a large Phase 3 lung‑cancer trial positioned to compete with Merck’s Keytruda; successful results would target a high‑value oncology market and materially improve growth prospects. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study
• Positive Sentiment: Early‑stage autoimmune program — PF‑08065010 entered Phase 1, increasing the company’s early‑stage pipeline breadth and optionality. Small near‑term value but positive for long‑term growth optionality. Pfizer’s New Autoimmune Candidate PF-08065010 Enters Phase 1
• Positive Sentiment: Pipeline diligence — Pfizer advanced PF‑07248144 into a drug–interaction study, a technical but constructive step showing steady, low‑noise pipeline progress. Pfizer Advances PF-07248144 With New Drug–Interaction Study
• Positive Sentiment: Strategic vaccine move — discussions around licensing Novavax’s Matrix‑M adjuvant (and a reported licensing deal) could strengthen Pfizer’s vaccine platform and future product differentiation. Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s Vaccine Platform Strategy?
• Positive Sentiment: Bullish derivatives flow — unusually large options activity (about 446,836 calls traded) signals some traders are positioning for upside, which can amplify intraday volatility and reflect optimism about upcoming catalysts.
• Neutral Sentiment: Analyst preview — a Seeking Alpha earnings preview expects another beat for Q1, reinforcing the view that Pfizer can continue to exceed EPS expectations even as revenue mix evolves. Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
• Neutral Sentiment: CEO commentary — CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. may be losing ground to China in health research. This draws attention to regulatory/political risk but is not a direct financial catalyst. Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor skepticism on valuation/growth — opinion pieces question whether Pfizer is a cheap dividend or a value trap and highlight post‑COVID pricing and revenue slowdown risks, which can justify cautious selling or lower multiples. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?
• Negative Sentiment: Revenue/pricing concerns — analysis questioning Pfizer’s pricing strategy and post‑COVID revenue trajectory keeps near‑term top‑line uncertainty front‑of‑mind for investors. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a "neutral" rating and a $26.00 target price on the stock. Scotiabank initiated coverage on Pfizer in a report on Thursday, November 13th. They issued a "sector outperform" rating and a $30.00 target price for the company. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an "equal weight" rating for the company in a research report on Friday, December 12th. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the company an "underperform" rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $27.88.

Pfizer Trading Down 1.7%

The firm has a market capitalization of $145.82 billion, a price-to-earnings ratio of 14.91 and a beta of 0.47. The company has a fifty day moving average price of $25.39 and a 200-day moving average price of $25.01. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer's dividend payout ratio is currently 100.00%.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently bought and sold shares of the stock. Norges Bank bought a new position in shares of Pfizer in the 2nd quarter valued at approximately $2,270,157,000. Vanguard Group Inc. grew its holdings in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company's stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Neuberger Berman Group LLC raised its position in shares of Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock worth $468,174,000 after buying an additional 5,978,927 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.